GlaxoSmithKline News

GlaxoSmithKline | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Apr 15 11:29 ET

GlaxoSmithKline | 6-K/A: Total Voting Rights and Capital

Apr 4 07:50 ET

GlaxoSmithKline | 6-K: Total Voting Rights and Capital

Apr 2 13:20 ET

GlaxoSmithKline | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-GSK plc(4.5%)

Mar 28 17:11 ET

GlaxoSmithKline | 6-K: Transaction Notification

Mar 26 07:49 ET

GlaxoSmithKline | F-3ASR: Automatic shelf registration statement of securities of well-known seasoned issuers

Mar 25 14:04 ET

GlaxoSmithKline | 6-K: GlaxoSmithKline releases notice of 2024 Annual General Meeting of Shareholders

Mar 25 09:43 ET

GlaxoSmithKline | 6-K: Transfer of Treasury Shares

Mar 22 12:52 ET

GlaxoSmithKline | 6-K: Transaction Notification

Mar 22 12:22 ET

GlaxoSmithKline | 6-K: Positive Ruby Phase Iii Data Show Potential for Jemperli (Dostarlimab) Combinations in More Patients with Primary Advanced or Recurrent Endometrial Cancer

Mar 18 09:59 ET

GlaxoSmithKline | 6-K: Transaction Notification

Mar 13 13:19 ET

GlaxoSmithKline | 6-K: Dr Hal Dietz Has Been Appointed a Member of the Nominations & Corporate Governance Committee

Mar 8 12:50 ET

GlaxoSmithKline | 6-K: Gsk Announces Positive Results from Dreamm-8 Phase Iii Trial for Blenrep Versus Standard of Care Combination in Relapsed/Refractory Multiple Myeloma

Mar 7 06:14 ET

GlaxoSmithKline | 6-K: Viiv Healthcare Announces Interim Data at Croi Indicating Superior Efficacy of Long-Acting Injectable Hiv Treatment Cabenuva (Cabotegravir + Rilpivirine) Compared to Daily Oral Therapy in Individuals Living with Hiv Who Have Adheren

Mar 6 11:13 ET

GlaxoSmithKline | 6-K: Glaxosmithkline 2023 Annual Report on Form 20-F

Mar 5 13:13 ET

GlaxoSmithKline | IRANNOTICE: IRANNOTICE

Mar 5 12:33 ET

GlaxoSmithKline | 20-F: Registration statement / Annual report / Transition report

Mar 5 12:18 ET

GlaxoSmithKline | 6-K: Viiv Healthcare Presents Phase I Clinical Trial Findings of a Cabotegravir Long-Acting Injectable Investigational Formulation Allowing at Least Four Months Between Doses

Mar 5 06:13 ET

GlaxoSmithKline | 6-K: Total Voting Rights and Capital

Mar 1 10:34 ET

GlaxoSmithKline | 6-K: Publication of Annual Report 2023

Mar 1 09:59 ET